Public Health Association

Public Health Vaccines (PHV) is a privately held biotechnology company focused on the development and commercialization of vaccines against emerging infectious diseases of global public health importance. The company utilizes a proven recombinant vesicular stomatitis virus (rVSV) vector platform, similar to the technology used in the successful Ervebo Ebola vaccine, to develop candidates for high-threat pathogens. PHV's lead programs include vaccine candidates for Marburg virus disease and Nipah virus infection, both of which have received significant funding from organizations such as BARDA and CEPI. By leveraging strategic partnerships with entities like Crozet BioPharma, PHV aims to accelerate the delivery of life-saving countermeasures for diseases with high epidemic potential. The company is headquartered in Cambridge, Massachusetts, and operates as a lean, virtual organization focused on clinical development and regulatory approval.